Circulating PD ‐1 (+) cells may participate in immune evasion in peripheral T‐cell lymphoma and chidamide enhance antitumor activity of PD‐1 (+) cells

These figures showed that the gene expression of PD ‐1 (+) cells in peripheral blood of PTCL patients was different from that of healthy controls (Figures#cam42097-fig-0001 and#cam42097-fig-0002), and anti ‐tumor effects of PD‐1 (+) cells were weaker than that of PD‐1 (‐) cells (Figures#cam42097-fig-0003 and#cam42097-fig-0004), while chidamide could normalize tumor immunity by regulating immune ‐associated genes of PD‐1 (+) cells (Fig. 5). AbstractPeripheral T ‐cell lymphoma (PTCL) is a heterogeneous disease with poor outcomes. We intend to explore the role of circulating PD‐1 (+) cells in tumor immune evasion in PTCL patients and the mechanism of chidamide as a regulator of immune‐associated medicine on PD‐1 (+) cells. Gene expression profiling ( GEP) was performed on circulating PD‐1 (+) cells from 22 PTCL patients and 13 healthy subjects, and circulating PD‐1 (−) cells from 2 PTCL patients. PD‐1 (+) cells were treated with chidamide, and the production IFN‐γ and cytotoxicity were analyzed. GEP were performed on circulating PD‐ 1 (+) cells from 2 PTCL patients treated with chidamide combined with chemotherapy and 1 patient treated with traditional chemotherapy. GEP showed that genes associated with innate immune response were abnormally expressed in PD‐1 (+) cells of PTCL patients compared with healthy subjects, meanwhil e the expression of CTLA‐4 was significantly higher in PD‐1 (+) cells than that of PD‐1 (−) cells. In vitro st...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research